Shares of ImmunoVaccine (TSE IMV) opened at 1.23 on Wednesday. ImmunoVaccine has a 52 week low of $0.57 and a 52 week high of $1.70. The firm’s market capitalization is $148.22 million. The company’s 50 day moving average price is $1.21 and its 200-day moving average price is $1.21.
In other ImmunoVaccine news, insider Pierre Labbé acquired 26,825 shares of the stock in a transaction dated Friday, July 28th. The stock was purchased at an average cost of C$1.22 per share, with a total value of C$32,726.50.
ImmunoVaccine Company Profile
Immunovaccine Inc is a Canada-based clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company’s DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications.
What are top analysts saying about ImmunoVaccine Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ImmunoVaccine Inc. and related companies.